Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elaine T. Lim is active.

Publication


Featured researches published by Elaine T. Lim.


Nature | 2012

Patterns and rates of exonic de novo mutations in autism spectrum disorders

Benjamin M. Neale; Yan Kou; Li Liu; Avi Ma'ayan; Kaitlin E. Samocha; Aniko Sabo; Chiao-Feng Lin; Christine Stevens; Li-San Wang; Vladimir Makarov; Pazi Penchas Polak; Seungtai Yoon; Jared Maguire; Emily L. Crawford; Nicholas G. Campbell; Evan T. Geller; Otto Valladares; Chad Shafer; Han Liu; Tuo Zhao; Guiqing Cai; Jayon Lihm; Ruth Dannenfelser; Omar Jabado; Zuleyma Peralta; Uma Nagaswamy; Donna M. Muzny; Jeffrey G. Reid; Irene Newsham; Yuanqing Wu

Autism spectrum disorders (ASD) are believed to have genetic and environmental origins, yet in only a modest fraction of individuals can specific causes be identified. To identify further genetic risk factors, here we assess the role of de novo mutations in ASD by sequencing the exomes of ASD cases and their parents (n = 175 trios). Fewer than half of the cases (46.3%) carry a missense or nonsense de novo variant, and the overall rate of mutation is only modestly higher than the expected rate. In contrast, the proteins encoded by genes that harboured de novo missense or nonsense mutations showed a higher degree of connectivity among themselves and to previous ASD genes as indexed by protein-protein interaction screens. The small increase in the rate of de novo events, when taken together with the protein interaction results, are consistent with an important but limited role for de novo point mutations in ASD, similar to that documented for de novo copy number variants. Genetic models incorporating these data indicate that most of the observed de novo events are unconnected to ASD; those that do confer risk are distributed across many genes and are incompletely penetrant (that is, not necessarily sufficient for disease). Our results support polygenic models in which spontaneous coding mutations in any of a large number of genes increases risk by 5- to 20-fold. Despite the challenge posed by such models, results from de novo events and a large parallel case–control study provide strong evidence in favour of CHD8 and KATNAL2 as genuine autism risk factors.


Neuron | 2013

Using Whole-Exome Sequencing to Identify Inherited Causes of Autism

Maria H. Chahrour; Michael E. Coulter; Sarn Jiralerspong; Kazuko Okamura-Ikeda; Klaus Schmitz-Abe; David A. Harmin; Mazhar Adli; Athar N. Malik; Alissa M. D’Gama; Elaine T. Lim; Stephan J. Sanders; Ganesh H. Mochida; Jennifer N. Partlow; Christine M. Sunu; Jillian M. Felie; Jacqueline Rodriguez; Ramzi Nasir; Janice Ware; Robert M. Joseph; R. Sean Hill; Benjamin Y. Kwan; Muna Al-Saffar; Nahit Motavalli Mukaddes; Asif Hashmi; Soher Balkhy; Generoso G. Gascon; Fuki M. Hisama; Elaine LeClair; Annapurna Poduri; Ozgur Oner

Despite significant heritability of autism spectrum disorders (ASDs), their extreme genetic heterogeneity has proven challenging for gene discovery. Studies of primarily simplex families have implicated de novo copy number changes and point mutations, but are not optimally designed to identify inherited risk alleles. We apply whole-exome sequencing (WES) to ASD families enriched for inherited causes due to consanguinity and find familial ASD associated with biallelic mutations in disease genes (AMT, PEX7, SYNE1, VPS13B, PAH, and POMGNT1). At least some of these genes show biallelic mutations in nonconsanguineous families as well. These mutations are often only partially disabling or present atypically, with patients lacking diagnostic features of the Mendelian disorders with which these genes are classically associated. Our study shows the utility of WES for identifying specific genetic conditions not clinically suspected and the importance of partial loss of gene function in ASDs.


PLOS Genetics | 2014

Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population.

Elaine T. Lim; Peter Würtz; Aki S. Havulinna; Priit Palta; Taru Tukiainen; Karola Rehnström; Tonu Esko; Reedik Mägi; Michael Inouye; Tuuli Lappalainen; Yingleong Chan; Rany M. Salem; Monkol Lek; Jason Flannick; Xueling Sim; Alisa K. Manning; Claes Ladenvall; Suzannah Bumpstead; Eija Hämäläinen; Kristiina Aalto; Mikael Maksimow; Marko Salmi; Stefan Blankenberg; Diego Ardissino; Svati H. Shah; Benjamin D. Horne; Ruth McPherson; Gerald K. Hovingh; Muredach P. Reilly; Hugh Watkins

Exome sequencing studies in complex diseases are challenged by the allelic heterogeneity, large number and modest effect sizes of associated variants on disease risk and the presence of large numbers of neutral variants, even in phenotypically relevant genes. Isolated populations with recent bottlenecks offer advantages for studying rare variants in complex diseases as they have deleterious variants that are present at higher frequencies as well as a substantial reduction in rare neutral variation. To explore the potential of the Finnish founder population for studying low-frequency (0.5–5%) variants in complex diseases, we compared exome sequence data on 3,000 Finns to the same number of non-Finnish Europeans and discovered that, despite having fewer variable sites overall, the average Finn has more low-frequency loss-of-function variants and complete gene knockouts. We then used several well-characterized Finnish population cohorts to study the phenotypic effects of 83 enriched loss-of-function variants across 60 phenotypes in 36,262 Finns. Using a deep set of quantitative traits collected on these cohorts, we show 5 associations (p<5×10−8) including splice variants in LPA that lowered plasma lipoprotein(a) levels (P = 1.5×10−117). Through accessing the national medical records of these participants, we evaluate the LPA finding via Mendelian randomization and confirm that these splice variants confer protection from cardiovascular disease (OR = 0.84, P = 3×10−4), demonstrating for the first time the correlation between very low levels of LPA in humans with potential therapeutic implications for cardiovascular diseases. More generally, this study articulates substantial advantages for studying the role of rare variation in complex phenotypes in founder populations like the Finns and by combining a unique population genetic history with data from large population cohorts and centralized research access to National Health Registers.


Neuron | 2013

Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders.

Elaine T. Lim; Soumya Raychaudhuri; Stephan J. Sanders; Christine Stevens; Aniko Sabo; Daniel G. MacArthur; Benjamin M. Neale; Andrew Kirby; Douglas M. Ruderfer; Menachem Fromer; Monkol Lek; Li Liu; Jason Flannick; Stephan Ripke; Uma Nagaswamy; Donna M. Muzny; Jeffrey G. Reid; Alicia Hawes; Irene Newsham; Yuanqing Wu; Lora Lewis; Huyen Dinh; Shannon Gross; Li-San Wang; Chiao-Feng Lin; Otto Valladares; Stacey Gabriel; Mark A. DePristo; David Altshuler; Shaun Purcell

To characterize the role of rare complete human knockouts in autism spectrum disorders (ASDs), we identify genes with homozygous or compound heterozygous loss-of-function (LoF) variants (defined as nonsense and essential splice sites) from exome sequencing of 933 cases and 869 controls. We identify a 2-fold increase in complete knockouts of autosomal genes with low rates of LoF variation (≤ 5% frequency) in cases and estimate a 3% contribution to ASD risk by these events, confirming this observation in an independent set of 563 probands and 4,605 controls. Outside the pseudoautosomal regions on the X chromosome, we similarly observe a significant 1.5-fold increase in rare hemizygous knockouts in males, contributing to another 2% of ASDs in males. Taken together, these results provide compelling evidence that rare autosomal and X chromosome complete gene knockouts are important inherited risk factors for ASD.


The New England Journal of Medicine | 2013

Ataxia, Dementia, and Hypogonadotropism Caused by Disordered Ubiquitination

David H. Margolin; Maria Kousi; Yee-Ming Chan; Elaine T. Lim; Jeremy D. Schmahmann; Marios Hadjivassiliou; Janet E. Hall; Ibrahim Adam; Andrew A. Dwyer; Lacey Plummer; Stephanie V. Aldrin; Julia O'Rourke; Andrew Kirby; Kasper Lage; Aubrey Milunsky; Jeff M. Milunsky; Jennifer A. Chan; E. Tessa Hedley-Whyte; Mark J. Daly; Nicholas Katsanis; Stephanie B. Seminara

BACKGROUND The combination of ataxia and hypogonadism was first described more than a century ago, but its genetic basis has remained elusive. METHODS We performed whole-exome sequencing in a patient with ataxia and hypogonadotropic hypogonadism, followed by targeted sequencing of candidate genes in similarly affected patients. Neurologic and reproductive endocrine phenotypes were characterized in detail. The effects of sequence variants and the presence of an epistatic interaction were tested in a zebrafish model. RESULTS Digenic homozygous mutations in RNF216 and OTUD4, which encode a ubiquitin E3 ligase and a deubiquitinase, respectively, were found in three affected siblings in a consanguineous family. Additional screening identified compound heterozygous truncating mutations in RNF216 in an unrelated patient and single heterozygous deleterious mutations in four other patients. Knockdown of rnf216 or otud4 in zebrafish embryos induced defects in the eye, optic tectum, and cerebellum; combinatorial suppression of both genes exacerbated these phenotypes, which were rescued by nonmutant, but not mutant, human RNF216 or OTUD4 messenger RNA. All patients had progressive ataxia and dementia. Neuronal loss was observed in cerebellar pathways and the hippocampus; surviving hippocampal neurons contained ubiquitin-immunoreactive intranuclear inclusions. Defects were detected at the hypothalamic and pituitary levels of the reproductive endocrine axis. CONCLUSIONS The syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4. These findings link disordered ubiquitination to neurodegeneration and reproductive dysfunction and highlight the power of whole-exome sequencing in combination with functional studies to unveil genetic interactions that cause disease. (Funded by the National Institutes of Health and others.).


PLOS Genetics | 2013

Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes

Xin He; Stephan J. Sanders; Li Liu; Silvia De Rubeis; Elaine T. Lim; James S. Sutcliffe; Gerard D. Schellenberg; Richard A. Gibbs; Mark J. Daly; Joseph D. Buxbaum; Matthew W. State; Bernie Devlin; Kathryn Roeder

De novo mutations affect risk for many diseases and disorders, especially those with early-onset. An example is autism spectrum disorders (ASD). Four recent whole-exome sequencing (WES) studies of ASD families revealed a handful of novel risk genes, based on independent de novo loss-of-function (LoF) mutations falling in the same gene, and found that de novo LoF mutations occurred at a twofold higher rate than expected by chance. However successful these studies were, they used only a small fraction of the data, excluding other types of de novo mutations and inherited rare variants. Moreover, such analyses cannot readily incorporate data from case-control studies. An important research challenge in gene discovery, therefore, is to develop statistical methods that accommodate a broader class of rare variation. We develop methods that can incorporate WES data regarding de novo mutations, inherited variants present, and variants identified within cases and controls. TADA, for Transmission And De novo Association, integrates these data by a gene-based likelihood model involving parameters for allele frequencies and gene-specific penetrances. Inference is based on a Hierarchical Bayes strategy that borrows information across all genes to infer parameters that would be difficult to estimate for individual genes. In addition to theoretical development we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis. Thus TADAs integration of various kinds of WES data can be a highly effective means of identifying novel risk genes. Indeed, application of TADA to WES data from subjects with ASD and their families, as well as from a study of ASD subjects and controls, revealed several novel and promising ASD candidate genes with strong statistical support.


PLOS Genetics | 2013

Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls

Li Liu; Aniko Sabo; Benjamin M. Neale; Uma Nagaswamy; Christine Stevens; Elaine T. Lim; Corneliu A. Bodea; Donna M. Muzny; Jeffrey G. Reid; Eric Banks; Hillary Coon; Mark A. DePristo; Huyen Dinh; Tim Fennel; Jason Flannick; Stacey Gabriel; Kiran Garimella; Shannon Gross; Alicia Hawes; Lora Lewis; Vladimir Makarov; Jared Maguire; Irene Newsham; Ryan Poplin; Stephan Ripke; Khalid Shakir; Kaitlin E. Samocha; Yuanqing Wu; Eric Boerwinkle; Joseph D. Buxbaum

We report on results from whole-exome sequencing (WES) of 1,039 subjects diagnosed with autism spectrum disorders (ASD) and 870 controls selected from the NIMH repository to be of similar ancestry to cases. The WES data came from two centers using different methods to produce sequence and to call variants from it. Therefore, an initial goal was to ensure the distribution of rare variation was similar for data from different centers. This proved straightforward by filtering called variants by fraction of missing data, read depth, and balance of alternative to reference reads. Results were evaluated using seven samples sequenced at both centers and by results from the association study. Next we addressed how the data and/or results from the centers should be combined. Gene-based analyses of association was an obvious choice, but should statistics for association be combined across centers (meta-analysis) or should data be combined and then analyzed (mega-analysis)? Because of the nature of many gene-based tests, we showed by theory and simulations that mega-analysis has better power than meta-analysis. Finally, before analyzing the data for association, we explored the impact of population structure on rare variant analysis in these data. Like other recent studies, we found evidence that population structure can confound case-control studies by the clustering of rare variants in ancestry space; yet, unlike some recent studies, for these data we found that principal component-based analyses were sufficient to control for ancestry and produce test statistics with appropriate distributions. After using a variety of gene-based tests and both meta- and mega-analysis, we found no new risk genes for ASD in this sample. Our results suggest that standard gene-based tests will require much larger samples of cases and controls before being effective for gene discovery, even for a disorder like ASD.


Journal of Clinical Investigation | 2012

DGAT1 mutation is linked to a congenital diarrheal disorder

Joel T. Haas; Harland S. Winter; Elaine T. Lim; Andrew Kirby; Brendan Blumenstiel; Matthew DeFelice; Stacey Gabriel; Chaim Jalas; David Branski; Carrie A. Grueter; Mauro S. Toporovski; Tobias C. Walther; Mark J. Daly; Robert V. Farese

Congenital diarrheal disorders (CDDs) are a collection of rare, heterogeneous enteropathies with early onset and often severe outcomes. Here, we report a family of Ashkenazi Jewish descent, with 2 out of 3 children affected by CDD. Both affected children presented 3 days after birth with severe, intractable diarrhea. One child died from complications at age 17 months. The second child showed marked improvement, with resolution of most symptoms at 10 to 12 months of age. Using exome sequencing, we identified a rare splice site mutation in the DGAT1 gene and found that both affected children were homozygous carriers. Molecular analysis of the mutant allele indicated a total loss of function, with no detectable DGAT1 protein or activity produced. The precise cause of diarrhea is unknown, but we speculate that it relates to abnormal fat absorption and buildup of DGAT substrates in the intestinal mucosa. Our results identify DGAT1 loss-of-function mutations as a rare cause of CDDs. These findings prompt concern for DGAT1 inhibition in humans, which is being assessed for treating metabolic and other diseases.


The New England Journal of Medicine | 2013

Germline Mutations Affecting Gα11 in Hypoparathyroidism

Michael Mannstadt; Mark Harris; Bert Bravenboer; Sridhar Chitturi; Koen M.A. Dreijerink; David G. Lambright; Elaine T. Lim; Mark J. Daly; Stacey Gabriel; Harald Jüppner

In a study reported here, genomewide linkage analysis and whole-exome sequencing were used to identify two different heterozygous Gα11 mutations in autosomal-dominant, isolated hypoparathyroidism.


American Journal of Human Genetics | 2012

A Homozygous Mutation in KCTD7 Links Neuronal Ceroid Lipofuscinosis to the Ubiquitin-Proteasome System

John F. Staropoli; Amel Karaa; Elaine T. Lim; Andrew Kirby; Naser Elbalalesy; Stephen G. Romansky; Karen Leydiker; Scott H. Coppel; Rosemary Barone; Winnie Xin; Marcy E. MacDonald; Jose E. Abdenur; Mark J. Daly; Katherine B. Sims; Susan L. Cotman

Neuronal ceroid lipofuscinosis (NCL) is a genetically heterogeneous group of lysosomal diseases that collectively compose the most common Mendelian form of childhood-onset neurodegeneration. It is estimated that ∼8% of individuals diagnosed with NCL by conservative clinical and histopathologic criteria have been ruled out for mutations in the nine known NCL-associated genes, suggesting that additional genes remain unidentified. To further understand the genetic underpinnings of the NCLs, we performed whole-exome sequencing on DNA samples from a Mexican family affected by a molecularly undefined form of NCL characterized by infantile-onset progressive myoclonic epilepsy (PME), vision loss, cognitive and motor regression, premature death, and prominent NCL-type storage material. Using a recessive model to filter the identified variants, we found a single homozygous variant, c.550C>T in KCTD7, that causes a p.Arg184Cys missense change in potassium channel tetramerization domain-containing protein 7 (KCTD7) in the affected individuals. The mutation was predicted to be deleterious and was absent in over 6,000 controls. The identified variant altered the localization pattern of KCTD7 and abrogated interaction with cullin-3, a ubiquitin-ligase component and known KCTD7 interactor. Intriguingly, murine cerebellar cells derived from a juvenile NCL model (CLN3) showed enrichment of endogenous KCTD7. Whereas KCTD7 mutations have previously been linked to PME without lysosomal storage, this study clearly demonstrates that KCTD7 mutations also cause a rare, infantile-onset NCL subtype designated as CLN14.

Collaboration


Dive into the Elaine T. Lim's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark J. Daly

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew Kirby

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Li Liu

Carnegie Mellon University

View shared research outputs
Researchain Logo
Decentralizing Knowledge